Purdy’s Wharf Tower II
Suite 2001 1969 Upper Water Street
Halifax, NS B3J 3R7
Canada
902 442 0653
https://www.sonanano.com
Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. David Andrew Regan | Chief Executive Officer | 190,23k | N/A | 1969 |
Mr. Robert William George Randall CPA | CFO & Corporate Secretary | 46,18k | N/A | 1963 |
Dr. Len Pagliaro Ph.D. | CSO & Director | 159,97k | N/A | N/A |
Dr. Kulbir Singh Ph.D. | Co-Founder & Head of R&D | N/A | N/A | N/A |
Dr. Mike McAlduff | Director of R&D & Production and Founder | N/A | N/A | N/A |
Dr. Gerrard Marangoni | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | N/A |
Mr. Darren Rowles | Head of Diagnostics | 138,28k | N/A | 1979 |
Sona Nanotech Inc. operates as a nanotechnology life sciences company. It develops targeted hyperthermia therapy for cancer treatment; and nanomedical therapy for the treatment of colorectal cancer. The company also develops gold nanoparticle products; lateral flow assay rapid tests; bovine TB tests; and concussion screening tests. Sona Nanotech Inc. was founded in 2013 and is based in Halifax, Canada.
Sona Nanotech Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.